FENC
NASDAQ · Biotechnology
Fennec Pharmaceuticals Inc
$10.83
+0.23 (+2.12%)
Financial Highlights (FY 2026)
Revenue
55.15M
Net Income
-12,033,713
Gross Margin
91.6%
Profit Margin
-21.8%
Rev Growth
+207.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.6% | 38.7% | 38.7% | 38.7% |
| Operating Margin | -18.6% | -9.0% | -10.9% | -10.8% |
| Profit Margin | -21.8% | -8.2% | -9.3% | -8.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 55.15M | 74.30M | 77.18M | 58.63M |
| Gross Profit | 50.50M | 28.74M | 29.85M | 22.68M |
| Operating Income | -10,257,044 | -6,677,907 | -8,389,307 | -6,328,217 |
| Net Income | -12,033,713 | -6,101,542 | -7,191,772 | -4,667,510 |
| Gross Margin | 91.6% | 38.7% | 38.7% | 38.7% |
| Operating Margin | -18.6% | -9.0% | -10.9% | -10.8% |
| Profit Margin | -21.8% | -8.2% | -9.3% | -8.0% |
| Rev Growth | +207.2% | -7.2% | -5.1% | +12.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 73.87M | 65.09M | 81.68M |
| Total Equity | — | 146.21M | 144.26M | 154.72M |
| D/E Ratio | — | 0.51 | 0.45 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -10,258,131 | -9,610,170 | -10,191,915 | -7,485,493 |
| Free Cash Flow | — | -4,689,819 | -4,353,916 | -4,382,896 |